Cognito Therapeutics, an advanced clinical-stage neurotechnology company, is partnering with Ochsner Health to launch the Brain Health Collaboratory.[1] This collaboration creates the first regional platform in the US Gulf South for innovation in non-invasive brain health care.[1] The goal is to develop new models for the treatment of cognitive decline and Alzheimer's disease in both urban and rural communities.[1] The organization combines Cognito's Spectris investigative technology with Ochsner's clinical network.[1] They plan to develop a Brain Health Index to track cognitive health, disease progression, and response to treatment in real-world settings.[1] The program explores the integration of Spectris therapy into clinical practice for patients with cognitive decline.[1] This initiative follows the first Brain Health Collaboratory from November 2025 with the West Virginia University Rockefeller Neuroscience Institute.[1] The goal is to create a network of such centers to accelerate the translation of therapies from research into practice.[1]